IQWiG finds considerable added benefit for Keytruda in lung cancer
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether pembrolizumab in lung cancer has an added benefit over the appropriate comparator therapy.
Marketed by US pharma giant Merck & Co (NYSE: MRK) as Keytruda, pembrolizumab) been available since July this year for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express the T-cell receptor ligand PD-L1 and who have received a prior chemotherapy regimen, having originally been approved for melanoma. The drug generated $919 million in sales for the first nine months of 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze